Ben Atkins
Vice President of Investor Relations & Corporate Communications
[Audio Gap]
Cary Vance
Independent Non-Executive Chairman & Interim CEO
[Audio Gap] In each case, we believe our products are best from a clinical perspective, but also that they speed up the time to graft, the time to heal, which is extremely important for the patient and potential complications, but also important for the hospital that is trying to — that is striving to make economic progress themselves.
And so PermeaDerm is a biosynthetic dressing that protects the wound, that stabilizes the wound. And then depending on the wound size, and we’re getting much more into trauma as well, there is a need for a scaffolding-type technology to build up the wound. And so we have this collagen-based dermal matrix that not only builds that up, but also helps in revascularizing and preparing the wound for graft.
And then, of course, our RECELL product. And the RECELL product is time tested in terms of its ability to be effective. And of course, over the last year, we’ve moved from a more manual process to a more automated process that helps facilitate healing and using the patient’s own skin and a small part of that skin so that they don’t have those harvested graft donor sites that are oftentimes painful and problematic. And then finally, again, PermeaDerm is a great source of protection and healing in that process.
What’s important for this company is to get to a point of being data-driven. And so we’ll do that in every
Read the full article here
